Randomized trial of telmisartan and/or enalapril on renoprotective effects for patients of chronic renal diseases with hypertension.

Randomized trial of telmisartan and/or enalapril on renoprotective effects for patients of chronic renal diseases with hypertension. - Telmisartan, Enalapril vs Combination for Hypertension and Nephropathies: Intervensive Controlled trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000299

Enrollment

150

Registered

2005-12-21

Start date

2005-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Diseases

Interventions

Termisartan 20-80 mg daily, over 1 year Enalapril 2.5 to 10 mg daily, over 1 year Termisartan 20 to 80 mg and enalapril 2.5 to 10 mg daily, over 1 year

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with hypertension (blood pressure over 130/80 mmHg) and proteinuria (over plus-minus by dipstick).

Exclusion criteria

Exclusion criteria: Patients with allergy for angiotensin converting enzyme-inhibitor or angiotensin receptor blocker, liver injury, or pregnancy. Patients who are inadequate to entry this study by physicians in charge.

Design outcomes

Primary

Measure	Time frame
Effects of treatments with angiotensin converting enzyme-inhibitor &/or angiotensin receptor blocker on blood pressure, excretion of urinary protein, serum creatinine level and creatinine clearance.	—

Secondary

Measure	Time frame
Adverse effects of angiotensin converting enzyme-inhibitor &/or angiotensin receptor blocker.	—

Countries

Japan

Contacts

Public ContactKeigyou Yoh

Institute of Clinical Medicine, University of Tsukuba Division of Nephrology

kidney@md.tsukuba.ac.jp029-853-3202

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026